NHS England is developing a Single National Formulary to reduce variation in prescribing guidance and support faster access to clinically and cost-effective medicines. Set out in the 10 Year Health Plan for England, the programme will replace multiple local categorisation systems with one evidence-based digital source embedded in clinical workflows and decision-support tools. Implementation will begin with selected therapy areas and early adopter integrated care boards before wider rollout. National oversight, digital integration and standardised prescribing categories will underpin the transition while clinicians retain autonomy over individual treatment decisions.
Standardising Local Prescribing Guidance
Access to medicines can vary after a treatment has received a positive technology appraisal from the National Institute for Health and Care Excellence. NHS commissioners are responsible for funding eligible patients within three months, but local formularies still determine how medicines are categorised and used within care pathways. These formularies commonly use colours or other labels to indicate prescribing restrictions, including whether a medicine should be initiated or managed by a specialist.
At least 51 categories are currently used across England, creating a system that is complicated and inconsistent between local areas. The Single National Formulary will introduce a common categorisation framework designed to make prescribing guidance more consistent and easier to use. Half of England’s 26 integrated care boards, including some working through clustered arrangements, are expected to move to the new categories by December 2026. The remaining boards are scheduled to adopt them by July 2027.
Must Read: NHS Sets New Maternal Care Standards
Early adopter areas include parts of London, Greater Manchester, Essex, Norfolk and Suffolk, West Yorkshire, Hampshire and the Isle of Wight, Humber and North Yorkshire, Thames Valley and several combined commissioning areas. Their implementation experience will inform the wider rollout. The aim is not to remove local clinical judgement, but to reduce administrative inconsistency and give clinicians access to the same nationally aligned guidance wherever they work.
Phase One Focuses on Four Therapy Areas
The first phase will cover chronic heart failure, adult type 2 diabetes, ophthalmology and asthma. These areas were selected because they involve large patient populations, substantial service burdens and pathways in which access to innovation can be complex or inconsistent. They also align with national priorities, show existing prescribing variation and include opportunities for pathway change, genomic testing or emerging technologies.
The initial scope reflects the practical challenge of building a usable national system across a medicines landscape that includes more than 70,000 products used in the UK. Rather than attempting immediate comprehensive coverage, the programme will begin with a limited group of therapy areas and expand in stages. A second group will be considered before the end of 2026, including more complex areas where the formulary may support service readiness, pathway transformation, genomics and more consistent access.
The first digital product is planned for July 2027 and is expected to include between eight and 12 therapy areas. It will be embedded in prescribing systems and decision support tools so that clinicians can access recommendations during routine workflows. A national formulary committee will provide clinical and professional oversight and will work with the National Institute for Health and Care Excellence to translate national evidence into clear formulary recommendations. The programme is intended to develop into a comprehensive national prescribing and decision-making resource between late 2027 and mid-2030.
Measuring Access, Uptake and Outcomes
The programme’s stated measures of success focus on whether patients receive fairer access to medicines, whether clinically and cost-effective treatments are adopted more quickly and whether outcomes improve. Progress will also be assessed against wider health service priorities, including the transfer of care from hospital settings into community services. This links the formulary to broader changes in how treatment pathways are organised and delivered.
Implementation will run alongside existing commitments to increase the uptake of biosimilar and generic medicines. The programme also sits within wider plans for medicines investment over the next decade. These parallel priorities mean that faster adoption of new treatments will be considered alongside affordability, taxpayer value and existing commitments concerning other medicines.
Feedback from patients, clinicians, local health systems and industry is expected to inform development throughout the rollout. The early adopter phase will provide practical evidence on how standard categories work across different commissioning arrangements, while later expansion will test whether a single digital source can remain functional as more therapeutic areas are added.
The central operational change is the move from multiple local frameworks towards nationally consistent guidance embedded in clinical systems. The intended result is a clearer route from national recommendations to local prescribing practice, with fewer differences in terminology and fewer barriers created by separate formularies. Individual prescribing decisions will remain a matter of clinical judgement.
The Single National Formulary will introduce a common digital source of prescribing guidance across health services in England, beginning with four major therapy areas and a phased transition to standard categories. Early adopter systems will shape the national rollout, while a national committee will oversee recommendations and alignment with existing evidence. The first digital product is planned for July 2027, with broader expansion continuing to 2030. Success will depend on whether the programme reduces variation, supports timely adoption and improves access and outcomes without limiting clinicians’ authority over individual treatment decisions.
Source: NHS England
Image Credit: iStock
